- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
News
Article
Daily Derm Times: July 31, 2025
Author(s):
Key Takeaways
- Dermatology discussions emphasize topicals' role in managing pediatric atopic dermatitis, focusing on rapid-acting agents like ruxolitinib cream.
- Soligenix's Phase 2a trial for Behçet’s Disease shows dusquetide's efficacy in reducing oral ulcers, comparable to apremilast.
Catch up on dermatology news, highlights, and insights from the past 24 hours.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.
Clinical Community Forms Around Shared AD Challenges
At a recent Dermatology Times Case-Based Roundtable, attendees discussed several challenging AD cases.
Soligenix Reports Positive Phase 2a Data in Behçet’s Disease
The open-label trial showed dusquetide produced similar results to apremilast in reducing oral ulcers, pain, and ulcer duration.
Liza O’Dowd, MD, Discusses What Sets Icotrokinra Apart in Psoriasis Treatment Following NDA Submission
O'Dowd discusses J&J's recent NDA submission for icotrokinra in psoriasis.
How One Dermatologist is Revolutionizing Sun Care to Protect a New Generation
Whitney Hovenic, MD, highlights alarming trends in Gen Z's sun protection habits and introduces SPOOGE, a new sunscreen brand promoting skin health.
Common Sunscreen Allergens: What to Watch For
Kolansky identifies oxybenzone and fragrances as leading causes of sunscreen allergies.
Derm Dispatch: Adam Friedman, MD, FAAD, Unpacks the Science Behind CBD’s Role in UV Protection
Renata Block, DMSc, MMS, PA-C, interviews Adam Friedman, MD, FAAD, about his research into cannabidiol’s photoprotective potential, clinical trial design, and future directions.
Q&A with Jesse Lewin, MD, FACMS: Celebrating 10 Years of Innovations in Skin Cancer at Mount Sinai
Discover how the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai leads in innovative skin cancer care and research, celebrating a decade of excellence.
Leveraging Topicals to Address Severe Itch in Pediatric Atopic Dermatitis
In a discussion on pediatric AD management, Shanna Miranti, MPAS, PA-C, emphasized the enduring role of topical treatments for residual itch and flares, and highlighted the importance of rapid-acting agents such as ruxolitinib cream.
BMS Pursues Global Approval for Deucravacitinib for PsA
Deucravacitinib-treated patients achieved superior clinical responses compared to placebo at week 16 in both trials.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
